~~<i id='050533EBBF'><strike id='050533EBBF'><tt id='050533EBBF'><pre id='050533EBBF'></pre></tt></strike></i>~~

Home» explore» focus

focus

author：explore 2025-10-02 06:52:52 Page View：9

You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your inbox every Tuesday and Thursday.

Diabetes: Better shows data on app’s benefit with GLP-1s

Better Therapeutics announced top-line data suggesting that its prescription app for diabetes treatment, AspyreRx, can boost the impact of GLP-1 diabetes treatments. According to the release, a subgroup analysis of 160 participants in its pivotal trial on GLP-1 treatment found that the behavior modification app produced statistically significant reductions in A1C compared to a control group.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare explains how it will choose drugs for negotiation
Next article： How one medical school became remarkably diverse

explore

DIEP, the 'gold standard' of breast reconstruction, is under threat

AdobeIn1983,Iflewhomefromcollegetobewithmymotherasshewokeupfromamastectomy.Sheoptedoutofbreastrecons

Departing Stanford president retracts two papers

MarcTessierLavigne(center)retractedtwoSciencepapersonthedayhisresignationasStanfordpresidenttakeseff

Guidelines to prevent youth baseball injuries need more muscle

Apitcheratthe2018LittleLeagueWorldSeries.RobCarr/GettyImages“Weallknowthatweareinthemiddleofanepidem

AstraZeneca bets AAV gene therapy will still deliver the goods

AlastairGrant/APSengChenghasbeenworkingingenetherapyfornearlyaslongasgenetherapyhasbeenafield.Asayou

WSS

focus

focus

comprehensive

explore

AstraZeneca bets AAV gene therapy will still deliver the goods